SCHEMBL4773427

SCHEMBL4773427

CC(C)(C)OC(=O)NCc1ccc(N(Cc2cccc(Cl)c2Cl)S(C)(=O)=O)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.48
REN P00797 1/20 0.44
ALDH1A1 P00352 4/20 0.42
MAPT P10636 3/20 0.42
LMNA P02545 2/20 0.42
NAMPT P43490 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 1/20 0.39
DRD2 P14416 1/20 0.38
POLB P06746 1/20 0.38
MAPK1 P28482 1/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CA12 O43570 1/20 0.38
CA7 P43166 1/20 0.38
CA14 Q9ULX7 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4768251 0.92 GAA (0.42) GAARENALDH1A1MAPTLMNA
SCHEMBL4768255 0.91 GAA (0.42) GAARENALDH1A1MAPTLMNA
SCHEMBL4769629 0.85 GAA (0.52) GAAALDH1A1MAPTLMNAPOLB
SCHEMBL4773553 0.84 GAA (0.60) GAAALDH1A1MAPTLMNAPOLB
SCHEMBL4775222 0.84 GAA (0.49) GAARENALDH1A1MAPTLMNA
SCHEMBL4767900 0.84 GAA (0.49) GAARENALDH1A1MAPTLMNA
SCHEMBL4768047 0.83 REN (0.41) GAARENALDH1A1MAPTLMNA
SCHEMBL4791410 0.83 DRD2 (0.47) GAARENALDH1A1LMNACA1
SCHEMBL4767850 0.83 GAA (0.48) GAARENALDH1A1MAPTLMNA
SCHEMBL4776454 0.82 ALDH1A1 (0.46) GAARENALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 GAA 466/4885REN 4180/4885ALDH1A1 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.